| Primary |
| Psoriasis |
15.6% |
| Rash |
15.6% |
| Pruritus |
12.5% |
| Product Used For Unknown Indication |
9.4% |
| Eczema |
6.3% |
| Lichen Planus |
6.3% |
| Alopecia |
3.1% |
| Bed Bug Infestation |
3.1% |
| Blood Cholesterol Increased |
3.1% |
| Dermatitis Contact |
3.1% |
| Herpes Zoster |
3.1% |
| Inflammation |
3.1% |
| Photosensitivity Reaction |
3.1% |
| Porphyria |
3.1% |
| Seborrhoeic Dermatitis |
3.1% |
| Seborrhoeic Keratosis |
3.1% |
| Sleep Disorder |
3.1% |
|
| Cough |
9.1% |
| Rash |
9.1% |
| Accidental Exposure To Product |
4.5% |
| Anger |
4.5% |
| Application Site Burn |
4.5% |
| Cataract |
4.5% |
| Dermatitis Allergic |
4.5% |
| Drug Ineffective |
4.5% |
| Drug Withdrawal Syndrome |
4.5% |
| Eye Irritation |
4.5% |
| Hypersensitivity |
4.5% |
| Incorrect Route Of Drug Administration |
4.5% |
| Intraocular Pressure Increased |
4.5% |
| Myocardial Infarction |
4.5% |
| Off Label Use |
4.5% |
| Pain Of Skin |
4.5% |
| Pharmaceutical Product Complaint |
4.5% |
| Product Substitution Issue |
4.5% |
| Pruritus |
4.5% |
| Rash Macular |
4.5% |
|
| Secondary |
| Dry Skin |
22.2% |
| Pruritus |
16.7% |
| Product Used For Unknown Indication |
9.3% |
| Atrophic Vulvovaginitis |
7.4% |
| Psoriasis |
5.6% |
| Rash |
5.6% |
| Drug Use For Unknown Indication |
3.7% |
| Seborrhoeic Dermatitis |
3.7% |
| Vulvovaginal Discomfort |
3.7% |
| Vulvovaginal Dryness |
3.7% |
| Arthropod Bite |
1.9% |
| Bed Bug Infestation |
1.9% |
| Blood Cholesterol Increased |
1.9% |
| Dry Eye |
1.9% |
| Herpes Zoster |
1.9% |
| Hypersensitivity |
1.9% |
| Neuropathy Peripheral |
1.9% |
| Rash Generalised |
1.9% |
| Smoking Cessation Therapy |
1.9% |
| Subcorneal Pustular Dermatosis |
1.9% |
|
| Skin Atrophy |
15.8% |
| Dry Skin |
10.5% |
| Pruritus |
10.5% |
| Rash |
10.5% |
| Drug Hypersensitivity |
5.3% |
| Hypersensitivity |
5.3% |
| Keratopathy |
5.3% |
| Off Label Use |
5.3% |
| Product Substitution Issue |
5.3% |
| Scratch |
5.3% |
| Skin Striae |
5.3% |
| Squamous Cell Carcinoma Of Skin |
5.3% |
| White Blood Cell Count Decreased |
5.3% |
| Wound Secretion |
5.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.6% |
| Drug Use For Unknown Indication |
10.4% |
| Psoriasis |
9.7% |
| Hypertension |
5.6% |
| Pain |
4.2% |
| Depression |
3.7% |
| Eczema |
3.5% |
| Rheumatoid Arthritis |
3.1% |
| Diabetes Mellitus |
2.8% |
| Insomnia |
2.6% |
| Psoriatic Arthropathy |
2.6% |
| Rash |
2.3% |
| Hiv Infection |
2.2% |
| Anxiety |
2.2% |
| Hepatitis C |
2.2% |
| Crohn's Disease |
2.1% |
| Asthma |
2.0% |
| Osteoporosis |
1.8% |
| Pruritus |
1.8% |
| Blood Cholesterol Increased |
1.6% |
|
| Vomiting |
12.8% |
| Ventricular Septal Defect |
9.1% |
| Psoriasis |
7.9% |
| Rash |
7.3% |
| Urinary Tract Infection |
6.7% |
| Pulmonary Embolism |
5.5% |
| Drug Ineffective |
4.9% |
| Vitreous Haemorrhage |
4.9% |
| Weight Increased |
4.9% |
| Cardiac Failure Congestive |
4.3% |
| Death |
4.3% |
| Dehydration |
3.7% |
| White Blood Cell Count Decreased |
3.7% |
| Cerebral Infarction |
3.0% |
| Dyspnoea |
3.0% |
| Scleroderma |
3.0% |
| Stevens-johnson Syndrome |
3.0% |
| Type 2 Diabetes Mellitus |
3.0% |
| Blood Alkaline Phosphatase Increased |
2.4% |
| Depression |
2.4% |
|
